A publicly funded clinical trial conducted at an NHS site in England has found that psilocybin-assisted therapy was well tolerated and showed significant improvements in depression symptoms among adults with treatment-resistant major depressive disorder, according to a new study published in Nature Medicine. The trial is described as a two-arm, double-blind, randomized, placebo-controlled feasibility study involving 60 participants and a single 25-mg dose of psilocybin or placebo alongside standardized psychological support.
What the NHS trial found
The research was carried out at one National Health Service site in England and is presented as a feasibility trial designed to test whether psilocybin could be delivered safely and practically in a public healthcare setting. The authors report that participants receiving psilocybin showed significant improvements in depression symptoms, with good tolerability, and said the findings support further research in public healthcare environments.
The study also explored how the treatment could be implemented within the NHS. The paper notes that the work may help inform future delivery if licensing is achieved and funding models are agreed. The trial took place at South London and Maudsley NHS Foundation Trust, with study visits initially carried out at King’s College Hospital Clinical Research Facility and later at a refurbished community mental healthcare and research setting.
Why the findings matter for mental health research
Treatment-resistant depression remains a major challenge for clinicians and patients, and the study adds to growing interest in psychedelic-assisted therapy as a possible option when standard treatments have not worked. In the trial, eligible participants had major depressive disorder and had not responded adequately to at least two antidepressant treatments, or to one antidepressant plus psychotherapy.
The researchers say the result is important not only because of the symptom improvements, but also because it tests the treatment in a real NHS context. That is a key question for medical research in the UK, where potential therapies must work not just in controlled settings but also within routine public care.
How the trial was run
The article states that the study used a parallel-group, double-blind design and included an open-label extension for all participants after the main six-week follow-up period. The trial was approved by the London, Brent Research Ethics Committee and registered with the Medicines and Healthcare Products Regulatory Agency and ClinicalTrials.gov.
Researchers excluded participants with conditions or circumstances that could make psilocybin treatment unsafe, including bipolar disorder, psychotic disorder, substance dependence, dementia, recent suicide attempt, or significant medical or biochemical abnormalities. The publication emphasizes that the work was carried out under Good Clinical Practice standards.
What happens next
While the study is encouraging, it is still a feasibility trial rather than a definitive phase III test. That means larger studies will be needed to confirm how effective psilocybin-assisted therapy is, who is most likely to benefit, and how it could be integrated into NHS services safely and sustainably.
Even so, the results mark a notable step for UK medical research, especially as health systems continue searching for new approaches to severe depression that has resisted conventional treatment.
Source article: Nature Medicine study
Photo source: AI-generated or edited image
